Advertisement
AARD vs PHAT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AARD is a StrongBuy and PHAT is a Hold.
Momentum Indicator for AARD turns negative, indicating new downward trend
AARD saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator turned negative. In 22 of the 23 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for AARD turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 17 similar instances when the indicator turned negative. In 16 of the 17 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AARD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AARD entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for AARD's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +17.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where AARD advanced for three days, in 87 of 100 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
AARD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.407) is normal, around the industry mean (3.043). P/E Ratio (-0.432) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. AARD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AARD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PHAT's RSI Indicator dives into oversold zone
The RSI Oscillator for PHAT moved into overbought territory on October 23, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +5.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in 242 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
PHAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHAT as a result. In 57 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for PHAT turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for PHAT entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.349) is normal, around the industry mean (3.043). P/E Ratio (-4.592) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (2.511) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PHAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PHAT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 82 | |
P/E GROWTH RATING 1..100 | 10 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AARD | PHAT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 85% |
| Advances ODDS (%) | 4 days ago 87% | 5 days ago 84% |
| Declines ODDS (%) | 1 day ago 86% | 1 day ago 87% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AARD’s FA Score shows that 1 FA rating(s) are green while PHAT’s FA Score has 2 green FA rating(s).
- AARD’s FA Score: 1 green, 4 red.
- PHAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AARD’s TA Score shows that 4 TA indicator(s) are bullish while PHAT’s TA Score has 4 bullish TA indicator(s).
- AARD’s TA Score: 4 bullish, 4 bearish.
- PHAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
AARD (@Biotechnology) experienced а -63.23% price change this week, while PHAT (@Biotechnology) price change was -17.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
AARD is expected to report earnings on Nov 12, 2026.
PHAT is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AARD and
Correlation & Price change
A.I.dvisor indicates that over the last year, AARD has been loosely correlated with MGNX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if AARD jumps, then MGNX could also see price increases.
| Ticker / NAME | Correlation To AARD | 1D Price Change % | ||
|---|---|---|---|---|
| AARD | 100% | -64.81% | ||
| MGNX - AARD | 38% Loosely correlated | -38.02% | ||
| PULM - AARD | 31% Poorly correlated | +4.23% | ||
| TWST - AARD | 30% Poorly correlated | +3.28% | ||
| AZTR - AARD | 29% Poorly correlated | N/A | ||
| BCYC - AARD | 28% Poorly correlated | -2.47% | ||
More | ||||
PHAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with ALNY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then ALNY could also see price increases.
| Ticker / NAME | Correlation To PHAT | 1D Price Change % | ||
|---|---|---|---|---|
| PHAT | 100% | -18.12% | ||
| ALNY - PHAT | 44% Loosely correlated | -1.43% | ||
| QCLS - PHAT | 39% Loosely correlated | -10.98% | ||
| ATRA - PHAT | 36% Loosely correlated | -8.91% | ||
| AARD - PHAT | 32% Poorly correlated | -64.81% | ||
| KURA - PHAT | 32% Poorly correlated | -2.54% | ||
More | ||||